



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

15D

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/337,675 06/22/99 JAIN

R 029318/0497

FOLEY & LARDNER
3000 K STREET, SUITE 500
WASHINGTON DC 20007-5109

HM12/0829

EXAMINER

PULLIAM, A

ART UNIT	PAPER NUMBER
----------	--------------

1615

DATE MAILED:

08/29/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.

09/337,675

Applicant(s)

JAIN ET AL.

Examiner

Amy E Pulliam

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

Status

- 1) ☒ Responsive to communication(s) filed on 13 June 2000.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-22 and 25-35 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-22 and 25-35 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- a) ☐ All b) ☐ Some * c) ☐ None of the CERTIFIED copies of the priority documents have been:
1. ☐ received.
2. ☐ received in Application No. (Series Code / Serial Number) _____.
3. ☐ received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. & 119(e).

Attachment(s)

- 15) ☐ Notice of References Cited (PTO-892)
- 16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 17) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 8.

- 18) ☐ Interview Summary (PTO-413) Paper No(s). _____.
- 19) ☐ Notice of Informal Patent Application (PTO-152)
- 20) ☐ Other: _____.

Art Unit: 1615

DETAILED ACTION

Receipt is acknowledged of the Election, received June 13, 2000. Applicant's elected claims 1-22, and 25-36, with traverse.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, 2, 9, 13, 15, 16, 18, 19, 21, 30, 31, 34, and 34 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 9, 13, 15, 16, 18, 19, 21, 30, 31, 34, and 35 recite the word "agent". It is unclear as to what applicant is specifically claiming, and it is recommended that this word be replaced with a more specific term, such as "nanoparticulate drug", which is cited in the specification.

Claims 1, 2, 30, 31, and 35 recite the phrase "effective average particle size". It is unclear as to what is meant by this phrase, and appropriate correction is required.

Claims 1, 30 and 35 recite the phrase "2 to 24 hours or longer". This broad limitation renders the claim indefinite, because it is unclear exactly how long the composition will provide controlled release of the drug.

Art Unit: 1615

A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949). In the present instance, claims 2 and 31 recite the broad recitation, "consisting of less than about 800 nm," and the claims also recite, "less than about 600 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 100 nm, and less than about 50 nm," which is the narrower statement of the range/limitation.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1615

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-22, and 25-35 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent 5,145,684 to Liversidge *et al.* (hereinafter Liversidge). Liversidge discloses dispersable particles made of a drug substance and a surface modifier adsorbed on the surface of the drug, to maintain an effective average particle size of less than about 400 nm, as well as the method of making the particles through wet grinding. Further, Liversidge teaches that of pharmaceutical formulations containing the nanoparticles, and their use in method of treating mammals (abstract). Liversidge further discloses the drug substance useful in this invention is a poorly soluble drug, chosen from the list in column 3, lines 53+. In addition, Liversidge teaches that the surface modifier of the invention can be selected from various polymers, oligomers, natural products and surfactants. Examples of excipients include gelatin, casein, lecithin, gum acacia and others, and examples of polymers include carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and others (c 4, l 34-55). Liversidge also teaches that pharmaceutical compositions according to this invention include the nanoparticles and a pharmaceutically acceptable carrier, which is well known in the art for making solid or liquid oral formulation (c 7, l 53-60). Liversidge does not teach the specific amounts of excipients present in the composition, however, it is the position of the examiner that based on the general teaching of the presence of excipients, and the teaching that Liversidge's composition can be formulated into well

Art Unit: 1615

known forms, including solid oral forms, it is the position of the examiner that the specific concentrations is a specific limitations which would be routinely determined by one of ordinary skill in the art through minimal experimentation, as being suitable, absent the presentation of some unusual and/ or unexpected results. The results must be those that accrue from the specific limitations. Further, it is the position of the examiner that the teaching of cellulose polymers in the composition reads on applicant's claim to both a surface stabilizer and a rate controlling polymer, because on page 12, lines 27-28, applicant states that a suitable surface stabilizer includes various polymers, therefore the cellulose polymers can perform both desired functions. One of ordinary skill in the art would have been motivated to produce a well known pharmaceutical dosage form, such as a tablet, which incorporates Liversidge's nanoparticles, and the necessary excipients, especially based on Liversidge's disclosure that his particles are intended for this exact purpose. One of ordinary skill in the art would expect a successful pharmaceutical dosage form. Therefore, this invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy E Pulliam whose telephone number is (703) 308-4710. The examiner can normally be reached on M-F 8:30-5:00.

Art Unit: 1615

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (703) 308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-7922 for regular communications and (703) 308-7922 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234.

Amy E. Pulliam
Patent Examiner
Art Unit 1615
August 21, 2000


THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600